Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Schabert

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Journal of Medical Economics|March 27, 2012
Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in GermanyLesley-Ann Miller, Chakkarin Burudpakdee, Anthony Zagar, et al.
Journal of Medical Economics|November 26, 2011
Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United StatesVernon F Schabert, Crystal Watson, Shravanthi R Gandra, et al.
Epilepsy & Behavior : E&B|August 11, 2022
Incidence of mental health conditions by seizure control among adults with epilepsy in the United StatesVernon F Schabert, Sean Stern, Louis Ferrari, et al.
Journal of Substance Abuse Treatment|July 4, 2006
Characterizing substance abuse programs that treat adolescentsTami L Mark, Xue Song, Rita Vandivort, et al.
Melanoma Research|April 18, 2015
Comparative healthcare costs in patients with metastatic melanoma in the USAChun-Lan Chang, Vernon F Schabert, Julie Munakata, et al.
Current Medical Research and Opinion|January 13, 2012
Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness studyV F Schabert, B Bruce, C F Ferrufino, et al.
Epilepsy & Behavior : E&B|January 26, 2024
Greater need for treatment optimization in patients with epilepsy initiating adjunctive therapy: Results of a retrospective claims analysis of antiseizure medication drug load in the United StatesGregory S Connor, David M Labiner, Vernon F Schabert, et al.
Postgraduate Medicine|June 12, 2014
Fesoterodine prescription fill patterns and evaluation of the YourWay patient support plan for patients with overactive bladder symptoms and physiciansJeffrey N Trocio, Linda Brubaker, Vernon F Schabert, et al.
International Journal of Rheumatic Diseases|December 16, 2014
Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in TaiwanYing-Ming Chiu, Hui-Chu Lang, Hsiao-Yi Lin, et al.
Journal of Medical Economics|April 24, 2014
Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritisJeffrey R Curtis, Vernon F Schabert, Jason Yeaw, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Journal of Medical Economics|March 27, 2012
Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in GermanyLesley-Ann Miller, Chakkarin Burudpakdee, Anthony Zagar, et al.
Journal of Medical Economics|November 26, 2011
Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United StatesVernon F Schabert, Crystal Watson, Shravanthi R Gandra, et al.
Epilepsy & Behavior : E&B|August 11, 2022
Incidence of mental health conditions by seizure control among adults with epilepsy in the United StatesVernon F Schabert, Sean Stern, Louis Ferrari, et al.
Journal of Substance Abuse Treatment|July 4, 2006
Characterizing substance abuse programs that treat adolescentsTami L Mark, Xue Song, Rita Vandivort, et al.
Melanoma Research|April 18, 2015
Comparative healthcare costs in patients with metastatic melanoma in the USAChun-Lan Chang, Vernon F Schabert, Julie Munakata, et al.
Current Medical Research and Opinion|January 13, 2012
Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness studyV F Schabert, B Bruce, C F Ferrufino, et al.
Epilepsy & Behavior : E&B|January 26, 2024
Greater need for treatment optimization in patients with epilepsy initiating adjunctive therapy: Results of a retrospective claims analysis of antiseizure medication drug load in the United StatesGregory S Connor, David M Labiner, Vernon F Schabert, et al.
Postgraduate Medicine|June 12, 2014
Fesoterodine prescription fill patterns and evaluation of the YourWay patient support plan for patients with overactive bladder symptoms and physiciansJeffrey N Trocio, Linda Brubaker, Vernon F Schabert, et al.
International Journal of Rheumatic Diseases|December 16, 2014
Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in TaiwanYing-Ming Chiu, Hui-Chu Lang, Hsiao-Yi Lin, et al.
Journal of Medical Economics|April 24, 2014
Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritisJeffrey R Curtis, Vernon F Schabert, Jason Yeaw, et al.
Pageof 3